Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is a biotechnology company focused on developing and commercializing innovative therapies in critical care and infectious disease. The company’s commercial portfolio include the first and only antibiotic developed specifically to treat Acinetobacter pathogens in adults; a vasopressor indicated to increase blood pressure in adults with septic or other distributive shock; and a broad-spectrum antibiotic to treat complicated intra-abdominal infections in adults. For more information, visit www.innovivaspecialtytherapeutics.com.